Efficacy and Safety of Intensive Blood Pressure Therapy Using Restricted Mean Survival Time – Insights from the SPRINT Trial

Restricted mean survival time has limited current use in cardiovascular clinical trials. It’s considered a translational statistic – a summary measure that can be readily understood by clinicians and patients. Restricted mean survival time, the area under the Kaplan-Meier curve, provides an intuitive method to assess the impact of an intervention. It complements current methods by quantifying treatment-related gains [days gained from reduction of major adverse cardiovascular events] and treatment-related losses [days lost from increase in serious adverse events] within a pre-defined timeframe.